ANI Pharmaceuticals
Develops rare-disease therapies, niche generics, and established prescription brands.
$72.83
After-hours close−0.01 (−0.01%)
At close$72.84(−0.91%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 110.75%Insiders 7.90%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 22.73M · Float 19.42M · 85.4% free float
Institutions13F, as of Jun 30, 2026
314 holders · 25.18M shares · 54 new positions · 174 increased · 89 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 2.96M | 13.01% | +211.2K | Aug 7, 2026 |
| Soleus Capital Management, L.P. | 867.8K | 3.82% | +47.5K | Aug 11, 2026 |
| Vanguard Capital Management LLC | 838.2K | 3.69% | +15.2K | Aug 13, 2026 |
| State Street Corp | 831.6K | 3.66% | +60.1K | Aug 7, 2026 |
| Tang Capital Management LLC | 707.5K | 3.11% | 0 | Aug 14, 2026 |
| Dimensional Fund Advisors LP | 623.5K | 2.74% | +92.3K | Aug 11, 2026 |
| American Century Companies Inc | 574.5K | 2.53% | +382.9K | Aug 12, 2026 |
| Arrowstreet Capital, Limited Partnership | 562.0K | 2.47% | −2.3K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 11.30% | 2.52M | 13G | Oct 17, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Muthusamy Shanmugam | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | 533.0K | 2.34% | Mar 2, 2026 |
| Nikhil Lalwani | director, officer: PRESIDENT & CEO | 344.5K | 1.52% | Aug 26, 2026 |
| Chad Gassert | officer: SVP - CORP. DEV. & STRATEGY | 233.4K | 1.03% | Mar 2, 2026 |
| Stephen P. Carey | officer: SVP & CFO | 174.7K | 0.77% | Jul 30, 2026 |
| Christopher Mutz | officer: HEAD OF RARE DISEASE | 91.3K | 0.40% | Mar 13, 2026 |
| Ori Gutwerg | officer: SVP, GENERICS | 75.5K | 0.33% | Aug 11, 2026 |
| Meredith Cook | officer: SR. VP, GENERAL COUNSEL & SEC. | 74.4K | 0.33% | Aug 13, 2026 |
| Krista Davis | officer: SVP, CHIEF HR OFFICER | 51.9K | 0.23% | Mar 10, 2026 |
| Thomas Haughey | director | 38.9K | 0.17% | Jun 10, 2026 |
| Patrick D. Walsh | director | 38.4K | 0.17% | May 13, 2026 |
1 ten-percent owner holds 1.82M shares by Form 4, outside the officers-and-directors figure above · 18 people have not refiled in the last 18 months (1.29M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 25, 2026 | Nikhil Lalwanidirector, officer: PRESIDENT & CEO | Sale | 5,400 | $74.30 | 344,489 |
| Aug 13, 2026 | Meredith Cookofficer: SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $75.48 | 74,424 |
| Aug 10, 2026 | Ori Gutwergofficer: SVP, GENERICS | Sale | 3,162 | $77.00 | 75,534 |
| Jul 29, 2026 | Stephen P. Careyofficer: SVP & CFO | Sale | 2,850 | $81.36 | 174,693 |
| Jul 13, 2026 | Meredith Cookofficer: SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $81.84 | 77,390 |
| Jul 2, 2026 | Stephen P. Careyofficer: SVP & CFO | Sale | 3,313 | $86.00 | 177,543 |
| Jun 29, 2026 | Stephen P. Careyofficer: SVP & CFO | Sale | 2,850 | $84.12 | 177,543 |
| Jun 12, 2026 | Meredith Cookofficer: SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $82.03 | 77,890 |
| Jun 8, 2026 | Thomas Haugheydirector | Sale | 2,000 | $80.88 | 38,878 |
| Jun 5, 2026 | Stephen P. Careyofficer: SVP & CFO | Sale | 3,312 | $80.00 | 180,393 |
CongressHouse and Senate disclosures
Not reported.